SciTech Development raised $5.5 million to advance ST-001 nanoFenretinide, a nanoparticle therapy for rare cancers including T-cell lymphoma. Its delivery platform improves drug effectiveness and safety, and the therapy has received FDA Orphan Drug Designation.
